Our Goal

At Cellphire, we are redefining what is possible in transfusion medicine.
Cellphire`s goal is to revolutionize hemostasis management through the development of the next generation platelet-based products that will efficiently stop bleeding. We believe that our products will ensure platelet availability to all patients regardless of location or environment.

Cellphire supports innovation in veterinary transfusion medicine.

Through our veterinary subsidiary, BodeVet®, we developed and launched the company’s first commercially available product, StablePlate RX® Canine, a canine freeze-dried platelet product with demonstrated efficacy in stopping bleeding in dogs. We are developing additional innovative transfusion medicine therapies for companion animals, including freeze-dried canine plasma. BodeVet® is also expanding its platelet work to support equine patients, as well as exotic animals such as elephants.

Our Facility

From discovery to manufacturing, Cellphire has the capability to deliver innovative therapeutic products.

Headquartered in Rockville, Maryland, our 32,000-square-foot facility includes 9,500 square feet of lab and clean-room manufacturing space.
StablePlate RX® Canine, Thrombosomes, and research products are manufactured onsite.
Our state-of-the-art cGMP facility consists of two separate manufacturing suites (one for veterinary and one for human products) that meet ISO 7 standards.
The quality control laboratory is equipped with all analytical equipment necessary to test each lot for acceptability and support our discovery team’s research in new products.

Cellphire Therapeutics, Inc. news

Contact supplier